Loading...
•
Mar 31
Protagonist Q1 2025 Earnings Report
Protagonist Therapeutics reported its financial results for the first quarter ended March 31, 2025, highlighting significant progress in its late-stage partnered assets and a strong cash position.
Key Takeaways
Protagonist Therapeutics announced a strong first quarter for 2025, driven by positive clinical trial results for rusfertide and icotrokinra, both progressing towards NDA filings by year-end. The company reported a net loss of $11.655 million, or $0.19 per basic and diluted share, and maintained a robust cash position of $697.9 million.
Positive top-line results from the rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) were announced, with full data selected for oral presentation at ASCO on June 1st.
Full dataset from the icotrokinra Phase 3 ICONIC-LEAD trial in plaque psoriasis (PsO) was presented at the 2025 AAD Meeting, and data from the adolescent subset at the World Congress of Pediatric Dermatology.
Positive top-line results from the icotrokinra Phase 2b ANTHEM trial in ulcerative colitis (UC) were announced, with data to be presented at a medical conference later in 2025.
The company's cash, cash equivalents, and marketable securities stood at $697.9 million as of March 31, 2025, providing a cash runway through at least the end of 2028.
Protagonist
Protagonist
Protagonist Revenue by Segment
Revenue by Segment
License and collaboration Revenue
CapyFin.com Forward Guidance
Protagonist Therapeutics anticipates continued advancement of its late-stage clinical programs, with potential NDA filings for rusfertide and icotrokinra by year-end 2025. The company also plans to progress its early-stage pipeline, including PN-881, into clinical safety and proof-of-concept studies starting in 2025, supported by a strong cash position.
Positive Outlook
- Rusfertide Phase 3 VERIFY trial data to be presented at ASCO on June 1st, indicating significant progress.
- Icotrokinra Phase 2b ANTHEM study results in UC lay the foundation for additional studies in both UC and Crohn's.
- Anticipated NDA filings for rusfertide and icotrokinra by year-end 2025.
- Strong cash position of $697.9 million provides a cash runway through at least the end of 2028, enabling independent pipeline progression.
- Advancement of pre-clinical candidates, including the oral IL-17 antagonist PN-881, and oral anti-obesity and oral hepcidin programs into clinical studies in 2025.
Challenges Ahead
- Future performance is subject to risks and uncertainties that could cause actual results to differ materially from anticipated outcomes.
- Ability to develop and commercialize product candidates is not guaranteed.
- Ability to earn milestone payments under collaboration agreements with Janssen and Takeda is not guaranteed.
- Operating in a competitive industry with competitors having greater resources poses a challenge.
- Obtaining and maintaining regulatory approval for product candidates is not guaranteed.